Clinical trials
Metabolic Diseases trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
67 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 8 |
| 2022 | 9 |
| 2023 | 6 |
| 2024 | 10 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 33 |
| Recruiting | 11 |
| Active, not recruiting | 8 |
| Terminated | 7 |
| Unknown status | 5 |
| Not yet recruiting | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 4 |
| Eli Lilly and Company | 4 |
| 89bio, Inc. | 3 |
| Akcea Therapeutics | 3 |
| Pfizer | 3 |
| Agios Pharmaceuticals, Inc. | 2 |
| CRISPR Therapeutics AG | 2 |
| Calcilytix Therapeutics, Inc., a BridgeBio company | 2 |
| Kastle Therapeutics, LLC | 2 |
| Laval University | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Metabolic Diseases | 67 |
| Endocrine System Diseases | 19 |
| Diabetes Mellitus | 18 |
| Glucose Metabolism Disorders | 18 |
| Diabetes Mellitus, Type 2 | 15 |
| Genetic Diseases, Inborn | 15 |
| Lipid Metabolism Disorders | 13 |
| Metabolism, Inborn Errors | 10 |
| Obesity | 10 |
| Cardiovascular Diseases | 8 |
Trials
Showing 51 to 67 of 67. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.